Please use this identifier to cite or link to this item:
Title: Prognostic heterogeneity of adult B‐cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3‐PBX1 treated with measurable residual disease‐oriented protocols
Author: Ribera, Jordi
Granada, Isabel
Morgades, Mireia
González, Teresa
Ciudad, Juana
Such, Esperanza
Calasanz, María José
Mercadal, Santiago
Coll, Rosa
González Campos, José
Tormo, Mar
García Cadenas, Irene
Gil, Cristina
Cervera, Marta
Barba, Pere
Costa, Dolors
Ayala, Rosa
Bermúdez, Arancha
Orfao, Alberto
Ribera, Josep Maria
Programa Español de Tratamiento en Hematología (PETHEMA) Group Spanish Society Of Hematology (SEHH)
Keywords: Pronòstic mèdic
Citogenètica humana
Human cytogenetics
Issue Date: 21-Sep-2021
Publisher: Wiley
Abstract: The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).
Note: Reproducció del document publicat a:
It is part of: British Journal of Haematology, 2021, vol. 194
Related resource:
ISSN: 1365-2141
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
bjh.17844.pdf160.02 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons